These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 8768755

  • 1. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
    Zhang R, Iyer RP, Yu D, Tan W, Zhang X, Lu Z, Zhao H, Agrawal S.
    J Pharmacol Exp Ther; 1996 Aug; 278(2):971-9. PubMed ID: 8768755
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS, Leeds JM, Fitchett J, Burckin T, Truong L, Spainhour C, Creek M, Levin AA.
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [Abstract] [Full Text] [Related]

  • 6. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.
    Cossum PA, Sasmor H, Dellinger D, Truong L, Cummins L, Owens SR, Markham PM, Shea JP, Crooke S.
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1181-90. PubMed ID: 8166890
    [Abstract] [Full Text] [Related]

  • 7. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.
    Zhang R, Lu Z, Zhang X, Zhao H, Diasio RB, Liu T, Jiang Z, Agrawal S.
    Clin Chem; 1995 Jun; 41(6 Pt 1):836-43. PubMed ID: 7768001
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
    Saijo Y, Perlaky L, Wang H, Busch H.
    Oncol Res; 1994 Jun; 6(6):243-9. PubMed ID: 7865900
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.
    Zhang R, Yan J, Shahinian HK, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR.
    Clin Pharmacol Ther; 1995 Jul; 58(1):44-53. PubMed ID: 7628182
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.
    Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S.
    Biochem Pharmacol; 1995 Mar 30; 49(7):929-39. PubMed ID: 7741765
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
    Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB, Sasmor H, Manoharan M, Levin AA.
    J Pharmacol Exp Ther; 2001 Mar 30; 296(3):890-7. PubMed ID: 11181921
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats.
    Cossum PA, Truong L, Owens SR, Markham PM, Shea JP, Crooke ST.
    J Pharmacol Exp Ther; 1994 Apr 30; 269(1):89-94. PubMed ID: 8169856
    [Abstract] [Full Text] [Related]

  • 13. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides.
    Sands H, Gorey-Feret LJ, Ho SP, Bao Y, Cocuzza AJ, Chidester D, Hobbs FW.
    Mol Pharmacol; 1995 Mar 30; 47(3):636-46. PubMed ID: 7700261
    [Abstract] [Full Text] [Related]

  • 14. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
    Zhang X, Zhang R, Zhao H, Cai H, Gush KA, Kerr RG, Pettit GR, Kraft AS.
    Cancer Res; 1996 Feb 15; 56(4):802-8. PubMed ID: 8631017
    [Abstract] [Full Text] [Related]

  • 15. Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion.
    Soucy NV, Riley JP, Templin MV, Geary R, de Peyster A, Levin AA.
    Birth Defects Res B Dev Reprod Toxicol; 2006 Feb 15; 77(1):22-8. PubMed ID: 16496297
    [Abstract] [Full Text] [Related]

  • 16. Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.
    Vincent SH, Painter SK, Krieter PA, Colletti AE, Lyszack E, Rosegay A, Dean D, Luffer-Atlas D, Miller RR, Cioffe C, Chiu SH.
    Drug Metab Dispos; 1996 Dec 15; 24(12):1369-77. PubMed ID: 8971144
    [Abstract] [Full Text] [Related]

  • 17. Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats.
    Agrawal S, Zhang X, Cai Q, Kandimalla ER, Manning A, Jiang Z, Marcel T, Zhang R.
    J Drug Target; 1998 Dec 15; 5(4):303-12. PubMed ID: 9713979
    [Abstract] [Full Text] [Related]

  • 18. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration.
    Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Yan J, Cai H, Diasio RB, Habus I, Jiang Z.
    Biochem Pharmacol; 1995 Aug 08; 50(4):571-6. PubMed ID: 7646565
    [Abstract] [Full Text] [Related]

  • 19. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.
    Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL.
    Mol Pharmacol; 1994 May 08; 45(5):932-43. PubMed ID: 8190109
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
    Agrawal S, Temsamani J, Tang JY.
    Proc Natl Acad Sci U S A; 1991 Sep 01; 88(17):7595-9. PubMed ID: 1881900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.